Article
The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.
Leukemia - 1 Feb 2018
Holmström M O, Martinenaite E, Ahmad S M, Met Ö, Friese C, Kjær L, Riley C H, Thor Straten P, Svane I M, Hasselbalch H C, Andersen M H
Abstract excerpt
The calreticulin (CALR) exon 9 mutations are found in ∼30% of patients with essential thrombocythemia and primary myelofibrosis. Recently, we reported spontaneous immune responses against the CALR mutations. Here, we describe that CALR-mutant (CALRmut)-specific T cells are able to specifically recognize CALRmut cells. First, we established a T-cell culture specific for a CALRmut epitope. These specific T cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.